Trial · NCT06360575
Adverse events58
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 58
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Crizotinib) | 6 | 18 | |
| other | Edema limbs | General disorders | Treatment (Crizotinib) | 4 | 18 | |
| other | Fatigue | General disorders | Treatment (Crizotinib) | 8 | 18 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Treatment (Crizotinib) | 1 | 18 | |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Treatment (Crizotinib) | 1 | 18 | |
| other | Constipation | Gastrointestinal disorders | Treatment (Crizotinib) | 4 | 18 | |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Crizotinib) | 4 | 18 | |
| other | Dyspepsia | Gastrointestinal disorders | Treatment (Crizotinib) | 1 | 18 | |
| other | Nausea | Gastrointestinal disorders | Treatment (Crizotinib) | 12 | 18 | |
| other | Vomiting | Gastrointestinal disorders | Treatment (Crizotinib) | 4 | 18 | |
| other | Gastrointestinal disorders - Other, specify | Gastrointestinal disorders | Treatment (Crizotinib) | 1 | 18 | |
| other | Urinary tract infection | Infections and infestations | Treatment (Crizotinib) | 1 | 18 | |
| other | Alanine aminotransferase increased | Investigations | Treatment (Crizotinib) | 7 | 18 | |
| other | Alkaline phosphatase increased | Investigations | Treatment (Crizotinib) | 5 | 18 | |
| other | Aspartate aminotransferase increased | Investigations | Treatment (Crizotinib) | 5 | 18 | |
| other | Blood bilirubin increased | Investigations | Treatment (Crizotinib) | 1 | 18 | |
| other | Creatinine increased | Investigations | Treatment (Crizotinib) | 3 | 18 | |
| other | Lymphocyte count decreased | Investigations | Treatment (Crizotinib) | 3 | 18 | |
| other | Weight loss | Investigations | Treatment (Crizotinib) | 2 | 18 | |
| other | White blood cell decreased | Investigations | Treatment (Crizotinib) | 1 | 18 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06360575/events